TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft nieuwe gegevens over de werkzaamheid en veiligheid op langere termijn aangekondigd voor Enspryng® [generieke naam: satralizumab (genetische recombinatie)], een pH-afhankelijke …
Author: Business Wire
Riassunto: Nuovi dati quadriennali mostrano una riduzione sostenuta delle recidive nei trattamenti con Enspryng di Chugai delle persone affette da disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha reso noti nuovi dati riguardanti la sicurezza e l’efficacia a lungo termine di Enspryng® [nome generico: satralizumab (ricombinazione genetica)], un anticorpo monoclonale umanizza…
Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
GENEVA–(BUSINESS WIRE)–Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics
REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics announced the appointment of Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release thir…
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of induc…
New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclona…
Contact Lenses Markets, 2026 by Modality (Reusable, v/s Disposable), Design (Spherical, Toric, Multifocal & Others), Material Type (Silicon Hydrogel, Hydrogel, Others) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Contact Lenses Market, By Modality (Reusable, v/s Disposable), By Design (Spherical, Toric, Multifocal & Others), By Material Type (Silicon Hydrogel, Hydrogel, Others), By Application, By Distribution Channel, B…
FGX International Celebrates World Sight Day by Announcing 17 Million Pairs of Donated Glasses
SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, a leading eyewear designer and manufacturer, celebrates 14 years of partnership with RestoringVision, the world’s largest nonprofit provider of reading glasses to people in need. Through this long-s…
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced results from a new analysis of UPLIZNA® (inebilizumab-cdon) in neuromyelitis optica spectrum disorder (NMOSD).
Global Phenylephrine Hydrochloride Market Insights (2021 to 2026) – Key Analysis and Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Phenylephrine Hydrochloride Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type” report has been added to ResearchAndMarkets.com’s offering. This rep…
Global Optical Sorter Market (2021 to 2026) – Growth, Trends, COVID-19 Impact and Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Sorter Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering. The optical sorter market is expected to register a CAGR of 10% over the for…
Haymarket Medical Network Launches Optometry Advisor
NEW YORK–(BUSINESS WIRE)–Haymarket Medical Network today launched Optometry Advisor, a new digital resource that empowers primary eye care physicians with comprehensive clinical, refractive, and pharmaceutical information. OptometryAdvisor.com meets …
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
DUBLIN–(BUSINESS WIRE)–New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
GenSight Biologics annonce l’octroi par la FDA de la désignation Fast Track pour GS030 comme traitement optogénétique de la rétinopathie pigmentaire
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, éligible PEA-PME), une société biopharmaceutique dédiée au développement et à la commercialisation des thérapies géniques innovantes pour le traitement de…
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of interim Phase 2 data wit…
ABIONYX Pharma initie des échanges avec la société IRIS Pharma, l’un des leaders mondiaux de la recherche préclinique et clinique en ophtalmologie, en vue d’un éventuel rapprochement stratégique
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 – ABNX), société biotech de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes, annonce aujourd’hui init…
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced …
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…